But, no matter what direction the general market takes, some stocks could stand out, potentially in 2025, and most ...

Compounded versions of the drugs tend to cost less and are popular at online ... the distribution of illegally marketed semaglutide and tirzepatide,” the spokesperson said.

Eli Lilly saw its shares close down 6.6% at $744.91 yesterday, after it revealed forecast for sales at the JP Morgan ...

Eli Lilly’s CEO Dave Ricks cited stocking levels and unexpected market dynamics in Q4 2024 in the GLP-1RA market.